Evidence Hub

Considerations for environmental sustainability in clinical trials: A case study simulation of the REVISE trial

Kanji S, Murthy S, Zytaruk N, Heels-Ansdell D, Deane A, Mehta S, Adhikari NKJ, Poole A et al.

Journal of critical care, 2026

1 citation

Abstract

PURPOSE

More environmentally sustainable clinical trials are needed. This case study simulation, based on a secondary analysis of the Re-Evaluating the Inhibition of Stress Erosions (REVISE) trial, was designed to estimate the carbon emission and monetary impact if the proton pump inhibitor had been switched from intravenous to enteral administration as soon as possible.

METHODS

In REVISE, only intravenous study drug was used, to avoid additional pharmacy costs associated with preparing study drug and placebo for enteral administration, to streamline trial management, and minimize transition-associated administration errors. The median duration of intravenous pantoprazole (or placebo) administration was 5 days; we assumed patients would transition to enteral lansoprazole on day 2 for the remaining intervention period. Greenhouse gas emissions from the intervention and waste generated were estimated using cost-based emissions factors for drugs and weight-based emission factors for waste. Monetary costs were derived from average acquisition costs from REVISE participating centers.

RESULTS

Allowing step-down to enteral lansoprazole on day 2 of an average 5-day course would have reduced greenhouse gas emissions by 28% compared with a 5-day intravenous pantoprazole regimen (9.84 vs. 13.6 kgCO₂e). Considering the entire trial, a complex intravenous/enteral intervention would have saved approximately 9000 kgCO2e and halved drug-related costs including aquisition, preparation and…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free